Advantage Alpha Capital Partners LP Arcellx, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $515 Million
- Q1 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 15,475 shares of ACLX stock, worth $854,065. This represents 0.21% of its overall portfolio holdings.
Number of Shares
15,475
Previous 22,673
31.75%
Holding current value
$854,065
Previous $1.26 Million
14.47%
% of portfolio
0.21%
Previous 0.24%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$217 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$211 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$207 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$169 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$130 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.42B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...